Claim centers on "Utilization of 에볼루션 바카라 무료’s CRISPR RNP technology"
[by Ji, Yong Jun] ToolGen, a gene editing company, announced on April 21 that it has filed a patent infringement lawsuit in the British court against Vertex Pharmaceuticals and its commercial partners, Lonza and RoslinCT, concerning the gene editing treatment CASGEVY.
ToolGen secured a 에볼루션 바카라 무료 for its 'CRISPR RNP (Ribonucleoprotein, protein-nucleic acid complex)' technology, a method for delivering Cas9 into cells in protein form, in Europe and Japan in October 2024. According to the company, CRISPR mitigates cytotoxicity commonly associated with DNA and mRNA delivery methods. It also offers excellent safety by eliminating the risk of foreign DNA integration into the genome and demonstrating low off-target effects. CRISPR RNP is widely employed in the development of therapeutics as well as in the genetic editing of plants and animals.
에볼루션 바카라 무료 is the world's first gene editing treatment to obtain marketing approval from the European Commission (EC) in February of last year, following its initial approval in the UK in November 2023. The therapy offers a novel treatment option for patients with sickle cell disease and β-thalassemia (Mediterranean anemia). A single dose is priced at approximately USD 2.2 million (around KRW 3.1 billion), and the product is anticipated to achieve blockbuster-level sales. In a related development, Vertex entered into a licensing agreement with Editas Medicine in December 2023, valued at USD 100 million, securing access to CRISPR Cas9 technology.
"Vertex's 에볼루션 바카라 무료 was developed using ToolGen's CRISPR RNP technology," said Ryu Jong-sang, CEO of ToolGen. "We expect Vertex to recognize the use of ToolGen's CRISPR-Cas9 and CRISPR RNP technologies and to provide fair compensation accordingly."
"This patent infringement lawsuit is not about restricting access to 에볼루션 바카라 무료 for patients in the UK but about ensuring that ToolGen receives fair compensation for its technology through a reasonable licensing agreement," Ryu further emphasized.